tirzepatide cardiovascular outcomes study The reason is harder to prove for event reduction in people who already have heart disease is that we don’t have the same kind of placebo-controlled cardiovascular-outcomes glp-3 New clinical trial: Zepbound quantity:1

tirzepatide cardiovascular outcomes study The reason is harder to prove for event reduction in people who already have heart disease is that we don’t have the same kind of placebo-controlled cardiovascular-outcomes glp-3 New clinical trial: Zepbound quantity:1

New clinical trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss ...

These injections are administered subcutaneously, with doses typically titrated upwards over several weeks

glp-3

quantity:1

Attenuated gastric ulcers, seizures, brain lesions, hepatomegaly, fatty liver, breakdown of liver glycogen, profound hypoglycemia and calcification in rats